Connexins and Atrial Fibrillation
2011; Lippincott Williams & Wilkins; Volume: 125; Issue: 2 Linguagem: Inglês
10.1161/circulationaha.111.075432
ISSN1524-4539
AutoresTakeshi Kato, Yu‐ki Iwasaki, Stanley Nattel,
Tópico(s)Nicotinic Acetylcholine Receptors Study
ResumoHomeCirculationVol. 125, No. 2Connexins and Atrial Fibrillation Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBConnexins and Atrial FibrillationFilling in the Gaps Takeshi Kato, MD, PhD, Yu-ki Iwasaki, MD, PhD and Stanley Nattel, MD Takeshi KatoTakeshi Kato From the Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. , Yu-ki IwasakiYu-ki Iwasaki From the Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. and Stanley NattelStanley Nattel From the Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. Originally published8 Dec 2011https://doi.org/10.1161/CIRCULATIONAHA.111.075432Circulation. 2012;125:203–206Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2011: Previous Version 1 Atrial fibrillation (AF) is an extremely common arrhythmia with important consequences and presently suboptimal therapeutic options.1 A great deal of research has been performed to understand the detailed mechanisms of AF, with the hope that a better appreciation of the fundamental determinants of arrhythmogenesis will lead to the development of novel, more successful treatment possibilities.2Article see p 216One aspect of AF pathophysiology that has elicited great interest has been changes in gap junction/connexin physiology. An important role for altered gap junction function and the potential importance of gap junctions as a therapeutic target for AF were first emphasized by Spach and Starmer over 15 years ago.3 Since that time, our understanding of gap junction physiology, biophysics, and molecular biology has increased enormously,4,5 as have studies on their role in AF pathogenesis and management.2Gap junctions contain transmembrane ion-channel proteins called connexins (Figure,panel A). Connexons (containing 6 connexin molecules each) in the gap junctions of adjacent cardiomyocytes line up and attach, transferring ions or molecules 1 y↑NA→NANALateralization of Cx40/Cx43Polontchouk24200115HumanChronic AF >1 y↓↑↓→NALateralization of Cx40/Cx43Kostin25200216HumanChronic AF >5 mo↓↑→→→Phosphorylated Cx40↑Nao26200317HumanChronic AF >6 mo→↓↑→NANACx40 ↓ in AF with complex activationKanagaratnam27200418HumanLone AF and AF with MVD↑NA↑NANACx40/Cx43 unchanged in lone AF,Wetzel28200519HumanPersistent AF >3 mo↓↓→→NAWilhelm29200620HumanChronic AF >3 mo→→→→NATakeuchi30200621HumanChronic AF up to 6 mo↓NA↑NA↑Lateralization of Cx43Rucker-Martin31200622HumanChronic AF >1 y (valve disease)↑↑↑NANACx40/Cx43 lateralization.Dhein32200823HumanPost-operative AF (CAD)→NA→NANACx40/43 reduced in arrested-heart surgery; not beating-heart or in AFLi33200924HumanPersistent AF (MVD, CAD)→NA→NANAGirmatsion34200925HumanPermanent AF >3 mo→NA↑↑↓Lateralization of Cx43Adam352010Abbreviations: ATP, atrial tachypacing; CAD, coronary artery disease; dephos, dephosphorylation; exp, expression; hetero, heterogeneity; SR, sinus rhythm; MVD, mitral valve disease; NA, not available.In this issue of Circulation, Igarashi et al report the results of a novel approach to controlling connexin expression in a porcine model of AF.42 The authors used an epicardial gene-painting approach to transfer Cx40 or Cx43 via adenoviral vectors to right and left atrial tissues, comparing gene-transferred with sham-operated animals. AF was induced by 2-second bursts of 42-Hz, 7.5-V atrial pacing separated by 2-second intervals to observe rhythm. Tachypaced sham dogs were in continuous AF after 5.8±0.6 days, whereas both Cx40- and Cx43-transferred dogs showed significantly increased probability of sinus rhythm, with no significant efficacy differences between Cx40- and Cx43-treated dogs. Atrial conduction was slowed in tachypaced sham dogs and substantially improved by connexin transfer. Tachypaced sham dogs showed significant decreases in total and phosphorylated Cx43 expression, with no change in Cx40 expression. Cx43 transfer normalized Cx43 expression in tachypaced dogs without affecting Cx40 expression; Cx40 transfer modestly increased Cx40 expression (by ≈20%) and did not affect Cx43 expression.The results of Igarashi et al are exciting in showing that enhancing connexin expression can have substantial AF-suppressing activity. They also point to a clear pathophysiological role of connexin downregulation in this AF model. In addition, they suggest that gene therapy approaches to increase connexin function and improve AF-related conduction abnormalities may be useful for treating AF. Furthermore, these results are consistent with another recent publication that showed efficacy of adenoviral-mediated Cx43 gene transfer in suppressing AF in a similar porcine model.20 Taken together, the results of these 2 investigations provide novel and important data about the role of connexins in AF.The study of Igarashi et al has a number of limitations that must be considered. First, no scrambled connexin gene control group was used to control for adenoviral effects per se, and therefore potential nonspecific effects cannot be excluded. Second, the porcine model of Igarashi et al displayed different properties from other prior animal AF models in which atrial tachypacing was used: Conduction was markedly slowed and refractoriness was unaffected, whereas previous models in which tachypacing was used to induce AF showed striking refractoriness abbreviation with very limited conduction slowing.43 Finally, the results of Cx40 gene transfer are difficult to reconcile with the observed physiology. Tachypaced AF dogs showed no Cx40 downregulation; Cx40 gene transfer increased Cx40 overall expression by only ≈20% without affecting intercalated-disk Cx40 expression and failed to alter strong downregulation of total (by ≈60%) and phosphorylated (by ≈90%) Cx43. Nevertheless, Cx40 gene transfer substantially improved conduction and suppressed AF; it is difficult to understand how this happened.Despite rapidly increasing knowledge about basic mechanisms underlying AF,2 many crucial mechanistic elements related to clinical AF management remain unresolved.44 The study of Igarashi et al is an important advance with respect to both pathophysiology and therapeutics. From the mechanistic perspective, it provides some of the most solid evidence to date on the potential participation of connexin dysfunction in AF. However, because the investigators studied a very specific animal model, much more work needs to be done to determine the relevance of their findings to various clinical forms of AF. From the therapeutic point of view, the study points the way to further development of connexin gene transfer therapy to treat AF. Overall, these results highlight the importance of learning much more about the role of gap junctions and their regulation in AF pathophysiology and management.AcknowledgmentsThe authors thank France Thériault for excellent secretarial assistance.Sources of FundingThis work was supported by the Canadian Institutes of Health Research (MOP 44365), the Quebec Heart and Stroke Foundation, the Fondation Leducq (European–North American Atrial Fibrillation Research Alliance), and the MITACS Network of Centers of Excellence.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.*Drs Kato and Iwasaki contributed equally to this work.Correspondence to Stanley Nattel, MD, Department of Medicine and Research Center, Montreal Heart Institute, Université de Montréal, 5000 Belanger St E, Montreal H1T1C8, Quebec, Canada. E-mail stanley.[email protected]orgReferences1. Dobrev D, Nattel S. New drugs for treatment of atrial fibrillation. Lancet. 2010; 375:1212–1223.CrossrefMedlineGoogle Scholar2. Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011; 121:2955–2968.CrossrefMedlineGoogle Scholar3. Spach MS, Starmer CF. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res. 1995; 30:337–344.CrossrefMedlineGoogle Scholar4. Tribulová N, Knezl V, Okruhlicová L, Slezák JMyocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol Res. 2008; 57(suppl 2):S1–S13.CrossrefMedlineGoogle Scholar5. Saffitz JE, Douglas P. Zipes lecture: biology and pathobiology of cardiac connexins: from cell to bedside. Heart Rhythm. 2006; 3:102–107.CrossrefMedlineGoogle Scholar6. Solan JL, Lampe PD. Connexin43 phosphorylation: structural changes and biological effects. Biochem J. 2009; 419:261–272.CrossrefMedlineGoogle Scholar7. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006; 354:2677–2688.CrossrefMedlineGoogle Scholar8. Firouzi M, Ramanna H, Kok B, Jongsma HJ, Koeleman BP, Doevendans PA, Groenewegen WA, Hauer RN. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res. 2004; 95:e29–e33.LinkGoogle Scholar9. Juang JM, Chern YR, Tsai CT, Chiang FT, Lin JL, Hwang JJ, Hsu KL, Tseng CD, Tseng YZ, Lai LP. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol. 2007; 116:107–112.CrossrefMedlineGoogle Scholar10. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL, Benjamin EJ, Alonso A, Ellinor PT, Barnard J, Chung MK, Smith JD. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011; 4:87–93.LinkGoogle Scholar11. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation. 1997; 96:1675–1685.LinkGoogle Scholar12. van der Velden HM, van Kempen MJ, Wijffels MC, van Zijverden M, Groenewegen WA, Allessie MA, Jongsma HJ. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol. 1998; 9:596–607.CrossrefMedlineGoogle Scholar13. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, Jongsma HJ. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res. 2000; 46:476–486.CrossrefMedlineGoogle Scholar14. Haugan K, Miyamoto T, Takeishi Y, Kubota I, Nakayama J, Shimojo H, Hirose M. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol. 2006; 99:71–79.CrossrefMedlineGoogle Scholar15. Ryu K, Li L, Khrestian CM, Matsumoto N, Sahadevan J, Ruehr ML, Van Wagoner DR, Efimov IR, Waldo AL. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am J Physiol. 2007; 293:H1231–H1241.CrossrefMedlineGoogle Scholar16. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol. 2007; 292:H1561–H1567.CrossrefMedlineGoogle Scholar17. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009; 105:1213–1222.LinkGoogle Scholar18. Hoyano M, Ito M, Kimura S, Tanaka K, Okamura K, Komura S, Mitsuma W, Hirono S, Chinushi M, Kodama M, Aizawa Y. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc Pathol. 2010; 19:e149–e157.CrossrefMedlineGoogle Scholar19. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Münz BM, Ml̈ler P, Steendijk P, Reil GH, Allessie MA, Böhm M, Neuberger HRAldosterone promotes atrial fibrillation [published online ahead of print August 4, 2011]. Eur Heart J.Google Scholar20. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, Bauer A. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011; 92:218–225.CrossrefMedlineGoogle Scholar21. Xiao P, Gao C, Fan J, Du H, Long Y, Yin Y. Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties. Regul Pept. 2011; 169:31–38.CrossrefMedlineGoogle Scholar22. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA, James AF. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol. 2011; 4:761–769.LinkGoogle Scholar23. Dupont E, Ko Y, Rothery S, Coppen SR, Baghai M, Haw M, Severs NJ. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation. 2001; 103:842–849.LinkGoogle Scholar24. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001; 38:883–891.CrossrefMedlineGoogle Scholar25. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002; 54:361–379.CrossrefMedlineGoogle Scholar26. Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T, Kobayashi S, Yano M, Hamano K, Matsuzaki M. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol. 2003; 91:678–683.CrossrefMedlineGoogle Scholar27. Kanagaratnam P, Cherian A, Stanbridge RD, Glenville B, Severs NJ, Peters NS. Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol. 2004; 15:206–216.CrossrefMedlineGoogle Scholar28. Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N, Hindricks G, Dhein S, Kottkamp H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart. 2005; 91:166–170.CrossrefMedlineGoogle Scholar29. Wilhelm M, Kirste W, Kuly S, Amann K, Neuhuber W, Weyand M, Daniel WG, Garlichs C. Atrial distribution of connexin 40 and 43 in patients with intermittent, persistent, and postoperative atrial fibrillation. Heart Lung Circ. 2006; 15:30–37.CrossrefMedlineGoogle Scholar30. Takeuchi S, Akita T, Takagishi Y, Watanabe E, Sasano C, Honjo H, Kodama I. Disorganization of gap junction distribution in dilated atria of patients with chronic atrial fibrillation. Circ J. 2006; 70:575–582.CrossrefMedlineGoogle Scholar31. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res. 2006; 72:69–79.CrossrefMedlineGoogle Scholar32. Dhein S, Duerrschmidt N, Scholl A, Boldt A, Schulte JS, Pfannmüller B, Rojas-Gomez D, Scheffler A, Haefliger JA, Doll N, Mohr FW. A new role for extracellular Ca2+ in gap-junction remodeling: studies in humans and rats. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377:125–138.CrossrefMedlineGoogle Scholar33. Li JY, Lai YJ, Yeh HI, Chen CL, Sun S, Wu SJ, Lin FY. Atrial gap junctions, NF-kappaB and fibrosis in patients undergoing coronary artery bypass surgery: the relationship with postoperative atrial fibrillation. Cardiology. 2009; 112:81–88.CrossrefMedlineGoogle Scholar34. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009; 6:1802–1809.CrossrefMedlineGoogle Scholar35. Adam O, Lavall D, Theobald K, Hohl M, Grube M, Ameling S, Sussman MA, Rosenkranz S, Kroemer HK, Schäfers HJ, Böhm M, Laufs U. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010; 55:469–480.CrossrefMedlineGoogle Scholar36. Hagendorff A, Schumacher B, Kirchhoff S, Lüderitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in connexin40-deficient mice analyzed by transesophageal stimulation. Circulation. 1999; 99:1508–1515.LinkGoogle Scholar37. Tuomi JM, Tyml K, Jones DL. Atrial tachycardia/fibrillation in the connexin 43 G60S mutant (oculodentodigital dysplasia) mouse. Am J Physiol. 2011; 300:H1402–H1411.CrossrefMedlineGoogle Scholar38. Beauchamp P, Yamada KA, Baertschi AJ, Green K, Kanter EM, Saffitz JE, Kléber AG. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res. 2006; 99:1216–1224.LinkGoogle Scholar39. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation. 2006; 114:110–118.LinkGoogle Scholar40. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation. 2007; 115:310–318.LinkGoogle Scholar41. Laurent G, Leong-Poi H, Mangat I, Moe GW, Hu X, So PP, Tarulli E, Ramadeen A, Rossman EI, Hennan JK, Dorian P. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol. 2009; 2:171–178.LinkGoogle Scholar42. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012; 125:216–225.LinkGoogle Scholar43. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008; 1:62–73.LinkGoogle Scholar44. Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol. 2011; 27:19–26.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Katritsis D and Morady F (2022) Atrial fibrillation Clinical Cardiac Electrophysiology, 10.1016/B978-0-323-79338-4.00022-4, (223-251.e1), . Patel K, Hwang T, Se Liebers C and Ng F (2022) Epicardial adipose tissue as a mediator of cardiac arrhythmias, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00565.2021, 322:2, (H129-H144), Online publication date: 1-Feb-2022. Bekiaridou A, Kartas A, Moysidis D, Papazoglou A, Baroutidou A, Papanastasiou A and Giannakoulas G (2022) The bidirectional relationship of thyroid disease and atrial fibrillation: Established knowledge and future considerations, Reviews in Endocrine and Metabolic Disorders, 10.1007/s11154-022-09713-0, 23:3, (621-630), Online publication date: 1-Jun-2022. Sun Y, Chao S, Ouyang H, Zhang W, Luo W, Nie Q, Wang J, Luo C, Ni G, Zhang L, Yang J, Feng H, Mao G and Li Z (2022) Hybrid nanogenerator based closed-loop self-powered low-level vagus nerve stimulation system for atrial fibrillation treatment, Science Bulletin, 10.1016/j.scib.2022.04.002, 67:12, (1284-1294), Online publication date: 1-Jun-2022. Saljic A, Friederike Fenner M, Winters J, Flethøj M, Eggert Eggertsen C, Carstensen H, Dalgas Nissen S, Melis Hesselkilde E, van Hunnik A, Schotten U, Sørensen U, Jespersen T, Verheule S and Buhl R (2021) Increased fibroblast accumulation in the equine heart following persistent atrial fibrillation, IJC Heart & Vasculature, 10.1016/j.ijcha.2021.100842, 35, (100842), Online publication date: 1-Aug-2021. Svinarich J (2021) The functional medicine approach to atrial fibrillation: can a cure for atrial fibrillation be found in the gut?, Current Opinion in Cardiology, 10.1097/HCO.0000000000000819, 36:1, (44-50), Online publication date: 1-Jan-2021. Serik S and Strona V (2021) Atrial fibrillation in diabetic patients., Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini, 10.15407/internalmed2021.02.103, 2021:2, (103-117), . Fakuade F, Tomsits P and Voigt N (2020) Connexin hemichannels in atrial fibrillation: orphaned and irrelevant?, Cardiovascular Research, 10.1093/cvr/cvaa308, 117:1, (4-6), Online publication date: 1-Jan-2021. Ai X, Yan J and Pogwizd S (2021) Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders, Cellular Signalling, 10.1016/j.cellsig.2021.110070, 86, (110070), Online publication date: 1-Oct-2021. Batista-Almeida D, Martins-Marques T, Ribeiro-Rodrigues T and Girao H (2020) The Role of Proteostasis in the Regulation of Cardiac Intercellular Communication Proteostasis and Disease, 10.1007/978-3-030-38266-7_12, (279-302), . Hoffman J, Trivedi A and Arora R (2020) Gene and cell based therapies for the prevention and treatment of supraventricular arrhythmias Emerging Technologies for Heart Diseases, 10.1016/B978-0-12-813704-8.00034-6, (761-780), . Lazzerini P, Laghi‐Pasini F, Acampa M, Srivastava U, Bertolozzi I, Giabbani B, Finizola F, Vanni F, Dokollari A, Natale M, Cevenini G, Selvi E, Migliacci N, Maccherini M, Boutjdir M and Capecchi P (2019) Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin‐6–Mediated Changes in Connexin Expression, Journal of the American Heart Association, 8:16, Online publication date: 20-Aug-2019. Trivedi A, Hoffman J and Arora R (2019) Gene therapy for atrial fibrillation - How close to clinical implementation?, International Journal of Cardiology, 10.1016/j.ijcard.2019.07.057, 296, (177-183), Online publication date: 1-Dec-2019. Lv X, Li J, Hu Y, Wang S, Yang C, Li C and Zhong G (2019) Overexpression of miR-27b-3p Targeting Wnt3a Regulates the Signaling Pathway of Wnt/ β -Catenin and Attenuates Atrial Fibrosis in Rats with Atrial Fibrillation , Oxidative Medicine and Cellular Longevity, 10.1155/2019/5703764, 2019, (1-13), Online publication date: 17-Apr-2019. Cheng W, Kao Y, Chao T, Lin Y, Chen S and Chen Y (2019) MicroRNA‐133 suppresses ZFHX3‐dependent atrial remodelling and arrhythmia, Acta Physiologica, 10.1111/apha.13322, 227:3, Online publication date: 1-Nov-2019. Tuomi J, Xenocostas A and Jones D (2018) Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib, Canadian Journal of Cardiology, 10.1016/j.cjca.2017.12.001, 34:3, (337-341), Online publication date: 1-Mar-2018. Gemel J, Su Z, Gileles-Hillel A, Khalyfa A, Gozal D and Beyer E (2017) Intermittent hypoxia causes NOX2-dependent remodeling of atrial connexins, BMC Cell Biology, 10.1186/s12860-016-0117-5, 18:S1, Online publication date: 1-Jan-2017. Lee H, Chen C, Tsai W, Lin H, Shiao Y, Sheu S, Wu B, Chen C and Lai W (2017) Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac Conduction, Scientific Reports, 10.1038/s41598-017-11416-5, 7:1, Online publication date: 1-Dec-2017. Katritsis D (2017) End points for catheter ablation of persistent atrial fibrillation, Heart Rhythm, 10.1016/j.hrthm.2017.01.015, 14:4, (484-485), Online publication date: 1-Apr-2017. Leybaert L, Lampe P, Dhein S, Kwak B, Ferdinandy P, Beyer E, Laird D, Naus C, Green C, Schulz R and Levy F (2017) Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications, Pharmacological Reviews, 10.1124/pr.115.012062, 69:4, (396-478), Online publication date: 1-Oct-2017. Desplantez T (2017) Cardiac Cx43, Cx40 and Cx45 co-assembling: involvement of connexins epitopes in formation of hemichannels and Gap junction channels, BMC Cell Biology, 10.1186/s12860-016-0118-4, 18:S1, Online publication date: 1-Jan-2017. Saravanan P, West A, Bridgewater B, Davidson N, Calder P, Dobrzynsky H, Trafford A and O'Neill S (2016) Omega-3 fatty acids do not alter P-wave parameters in electrocardiogram or expression of atrial connexins in patients undergoing coronary artery bypass surgery, Europace, 10.1093/europace/euv398, 18:10, (1521-1527), Online publication date: 1-Oct-2016. NAGIBIN V, EGAN BENOVA T, VICZENCZOVA C, SZEIFFOVA BACOVA B, DOVINOVA I, BARANCIK M and TRIBULOVA N (2016) Ageing Related Down-Regulation of Myocardial Connexin-43 and Up-Regulation of MMP-2 May Predict Propensity to Atrial Fibrillation in Experimental Animals, Physiological Research, 10.33549/physiolres.933389, (S91-S100), Online publication date: 29-Sep-2016. Heijman J, Algalarrondo V, Voigt N, Melka J, Wehrens X, Dobrev D and Nattel S (2015) The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis, Cardiovascular Research, 10.1093/cv
Referência(s)